Therapy News and Research

RSS

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

SynCardia Systems raises $14M to fund the rapid growth of Total Artificial Heart

Privately held SynCardia Systems, Inc. announced today that it had raised $14 million to fund the rapid growth of the only approved medical device that eliminates the symptoms and source of end-stage heart failure, the SynCardia temporary Total Artificial Heart. The SynCardia Total Artificial Heart is the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.

17 Dec 2013

Oral garlic does not reduce vaginal thrush, study finds

In a world-first study, led by the University of Melbourne and the Royal Women’s Hospital, researchers have found garlic does not significantly reduce vaginal candida (thrush).

17 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.

17 Dec 2013

New regulation for cancer-causing protein may help develop targeted therapies

Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati (UC) Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.

17 Dec 2013

Researchers treat osteogeneis imperfecta babies in utero by injecting bone-forming stem cells

Osteogeneis imperfecta (OI) is a congenital bone disease that causes stunted growth and repeated, painful fracturing. Ultrasound scans can reveal fractures already in the fetus, and now an international team of researchers from Sweden, Singapore and Taiwan have treated two babies in utero by injecting bone-forming stem cells.

17 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

Mayo Clinic researchers develop specialized catheter for transplanting stem cells into beating heart

Mayo Clinic researchers and colleagues in Belgium have developed a specialized catheter for transplanting stem cells into the beating heart. The novel device includes a curved needle and graded openings along the needle shaft, allowing for increased distribution of cells.

17 Dec 2013

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

The National Institute of Allergy and Infectious Diseases has awarded two seven-year grants to Brigham and Women's Hospital to fund the AIDS Clinical Trial Group Network.

16 Dec 2013

St. Joseph's Children's Hospital opens new Steinbrenner Children's Emergency/Trauma Center

St. Joseph's Children's Hospital in Tampa opened its new and expanded Steinbrenner Children's Emergency/Trauma Center Dec. 16, 2013. The hospital has the busiest children's emergency center in the region, and the larger, advanced facility will increase the community's access to the highest level of pediatric emergency care in the area.

16 Dec 2013

Study: Blue light proves to have powerful bacteria-killing ability

Blue light has proven to have powerful bacteria-killing ability in the laboratory. The potent antibacterial effects of irradiation using light in the blue spectra have now also been demonstrated in human and animal tissues. A series of groundbreaking articles that provide compelling evidence of this effect are published in Photomedicine and Laser Surgery, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers.

16 Dec 2013

Chest wall resection effective for recurrent mesothelioma

Salvage chest wall resection could lengthen survival in patients with isolated chest wall recurrence of malignant pleural mesothelioma, research indicates.

16 Dec 2013

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.

16 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Patients with recurrent glioblastoma multiforme treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.

16 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cells have a potential to develop into multiple cell types and divide without limit to replenish cells in human body throughout the life of individual.

16 Dec 2013

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer.

16 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Therapy News and Research

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

SynCardia Systems raises $14M to fund the rapid growth of Total Artificial Heart

Oral garlic does not reduce vaginal thrush, study finds

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

New regulation for cancer-causing protein may help develop targeted therapies

Researchers treat osteogeneis imperfecta babies in utero by injecting bone-forming stem cells

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Mayo Clinic researchers develop specialized catheter for transplanting stem cells into beating heart

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

St. Joseph's Children's Hospital opens new Steinbrenner Children's Emergency/Trauma Center

Study: Blue light proves to have powerful bacteria-killing ability

Chest wall resection effective for recurrent mesothelioma

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Experimental drug that targets macrophages decreases cancer's growth

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News